Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters?

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 6, Issue 3, 2005, Pages 151-153

  Davies, Justine ^a   Carr, Elaine ^a   Band, Margaret ^a   Morris, Andrew ^a   Struthers, Allan ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Atenolol; Augmentation; Blood pressure; Losartan

Indexed keywords

ATENOLOL; BRAIN NATRIURETIC PEPTIDE; LOSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL COMPLIANCE; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HEART LEFT VENTRICLE MASS; HEART RATE; HEMODYNAMIC PARAMETERS; HUMAN; HYPERTENSION; MALE; OUTCOME ASSESSMENT; PROGNOSIS; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE;

EID: 33144469517     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2005.022     Document Type: Article

References (14)

1. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
2. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355:253-9.
3. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery? J Hypertens 2005;23:551-6.
4. Waring WS, Goudsmit J, Marwick J, Webb DJ, Maxwell SR. Acute caffeine intake influences central more than peripheral blood pressure in young adults. Am J Hypertens 2003;16: 919-24.
5. Kelly RP, Gibbs HH, O'Rourke MF et al. Nitroglycerin has more favourable effects on left ventricular afterload than apparent from measurement of pressure in a peripheral artery. Eur Heart J 1990;11:138-44.
6. Chen CH, Ting CT, Lin SJ et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension 1995;25:1034-41.
7. Bhalla MA, Chiang A, Epshteyn VA et al. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol 2004;44:1047-52.
8. Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 2003;108:2987-92.
9. de Lemos JA, Morrow DA, Bentley JH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345: 1014-21.
10. Olsen MH, Wachtell K, Tuxen C et al. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertens 2005;23:1083-90.
11. Davies JI, Struthers AD. Pulse wave analysis and pulse wave velocity: a critical review of their strengths and weaknesses. J Hypertens 2003;21:463-72.
12. Wilkinson IB, McEniery CM, Cockcroft JR. Pulse waveform analysis and arterial stiffness: realism can replace evangelism and scepticism. J Hypertens 2005;23:213;author reply 213-14.
13. Lemogoum D, Flores G, Van den AW et al. Validity of pulse pressure and augmentation index as surrogate measures of arterial stiffness during beta-adrenergic stimulation. J Hypertens 2004;22:511-17.
14. Williams B. Pulse wave analysis and hypertension: evangelism versus scepticism. J Hypertens 2004;22:447-9.